Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | FECH | P22830 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214088 | 0.90 | PLK1 (0.45) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2213657 | 0.86 | LMNA (0.51) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2209440 | 0.83 | CYP1A1 (0.47) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2212499 | 0.83 | PLK1 (0.46) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2212820 | 0.83 | PLK1 (0.46) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2213223 | 0.83 | TSHR (0.48) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2212750 | 0.82 | MEN1 (0.52) | CYP1A1CYP1A2CYP1B1ALDH1A1LMNA | |
| SCHEMBL2209636 | 0.81 | CYP1A1 (0.47) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL4094987 | 0.81 | CYP1A1 (0.47) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2210837 | 0.79 | PLK1 (0.63) | PLK1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7161031-B2 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-01-09 | — | — | US | claimed |
| US-20050096484-A1 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | ONCONOVA THERAPEUTICS, INC. | 2005-05-05 | — | — | US | claimed |
| EP-1534284-B1 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7161031-B2 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1534284-A4 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1534284-A2 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050096484-A1 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | ONCONOVA THERAPEUTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2003072063-A2 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096484-A1 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | ARSA, MKI67, CCNA1 | PLK1 690/4885HDAC3 2201/4885HDAC4 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.